Ionis Pharmaceuticals
Open
$75.14
Prev. Close
$75.15
High
$75.18
Low
$75.08
Market Snapshot
$12.12B
-31.8
-3.04
$705.14M
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,402 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ionis Pharmaceuticals reported a substantial US$381.4 million loss for 2025, with Q4 revenue of US$203.3 million, influencing investor sentiment amid upcoming company earnings reports.
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,402 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Recently from Cashu
Regulatory Struggles in Gene Therapy: UniQure's Challenges and Industry Implications
Regulatory Challenges in Gene Therapy Development: A Focus on UniQure and Implications for the Industry The ongoing scrutiny faced by UniQure's gene therapy for Huntington's disease exemplifies the ch…
UniQure's Huntington's Gene Therapy Faces FDA Scrutiny Amid Regulatory Challenges
UniQure's Gene Therapy for Huntington's Disease Under Fire: A Regulatory Standoff UniQure faces heightened scrutiny from the U.S. Food and Drug Administration (FDA) for its gene therapy targeting Hunt…
Ionis Pharmaceuticals Faces Dual Perspectives on RNA-targeted Therapies Amid Competitive Landscape
Ionis Pharmaceuticals: Navigating the Complex Landscape of RNA-targeted Therapies Ionis Pharmaceuticals finds itself at a pivotal moment, with a recently observed interest from six analysts regarding…
Ionis Pharmaceuticals Reports Strong Q4 Earnings Amid Biotechnology Challenges and Future Growth Potential
Ionis Pharmaceuticals Shows Resilience with Better-than-Expected Q4 Results Ionis Pharmaceuticals Inc. highlights its financial resilience through the release of its fourth-quarter earnings, demonstra…